AstraZeneca’s spokesperson also pointed to AZD6234, a long-acting amylin in a phase 1 trial for obesity that’s due to complete in October. AstraZeneca GLP-1 Diabetes Biotech. Connect.

Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC) February 05, 2025 08:45 AM ...

A 12-week Phase 1 study evaluating the combination of this drug with Metsera’s amylin drug candidate is underway; preliminary data are expected by the end of this year or in early 2026.

Our phase 1 study of a single intravenous infusion of RP-A501, a recombinant AAV9 carrying the full-length LAMP2B transgene, administered to seven male patients with Danon disease showed that most ...